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Background: Due to the high prevalence of viral infections having no specific treatment and the constant
appearance of resistant viral strains, the development of novel antiviral agents is essential. The aim of this study was
to evaluate the antiviral activity against bovine viral diarrhea virus, herpes simplex virus type 1 (HSV-1), poliovirus
type 2 (PV-2) and vesicular stomatitis virus of organic (OE) and aqueous extracts (AE) from: Baccharis
gaudichaudiana, B. spicata, Bidens subalternans, Pluchea sagittalis, Tagetes minuta and Tessaria absinthioides. A
characterization of the antiviral activity of B. gaudichaudiana OE and AE and the bioassay-guided fractionation of
the former and isolation of one active compound is also reported.
Methods: The antiviral activity of the OE and AE of the selected plants was evaluated by reduction of the viral
cytopathic effect. Active extracts were then assessed by plaque reduction assays. The antiviral activity of the most
active extracts was characterized by evaluating their effect on the pretreatment, the virucidal activity and the effect
on the adsorption or post-adsorption period of the viral cycle. The bioassay-guided fractionation of
B. gaudichaudiana OE was carried out by column chromatography followed by semipreparative high performance
liquid chromatography fractionation of the most active fraction and isolation of an active compound. The antiviral
activity of this compound was also evaluated by plaque assay.
Results: B. gaudichaudiana and B. spicata OE were active against PV-2 and VSV. T. absinthioides OE was only active
against PV-2. The corresponding three AE were active against HSV-1. B. gaudichaudiana extracts (OE and AE) were
the most selective ones with selectivity index (SI) values of 10.9 (PV-2) and >117 (HSV-1). For this reason, both
extracts of B. gaudichaudiana were selected to characterize their antiviral effects. Further bioassay-guided
fractionation of B. gaudichaudiana OE led to an active fraction, FC (EC50=3.1 μg/ml; SI= 37.9), which showed antiviral
activity during the first 4 h of the viral replication cycle of PV-2 and from which the flavonoid apigenin (EC50 = 12.2 ±
3.3 μM) was isolated as a major compound.
Conclusions: The results showed that, among the species studied, B. gaudichaudiana seemed to be the most
promising species as a source of antiviral agents.
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Antiviral drugs for diseases caused by herpesviruses, ret-
roviruses, orthomyxoviruses, hepatitis B virus and hepa-
titis C virus (HCV) are currently commercially available
[1]. However, due to the high prevalence of viral infec-
tions for which there are no specific treatment and the
constant appearance of new resistant viral strains, the
development of novel antiviral agents is essential.
Natural products have proved to be an important
source of lead molecules and many extracts and com-
pounds of plant origin with antiviral activity have been
reported [2].
The great diversity of plants growing in Argentina offers
interesting possibilities of finding novel antiviral com-
pounds from a natural origin. Asteraceae is the most nu-
merous and diverse plant family in our country and is
highly promising from a pharmacological perspective [3].
The aim of this study was to evaluate the antiviral activ-
ity against bovine viral diarrhea virus (BVDV), herpes
simplex virus type 1 (HSV-1), poliovirus type 2 (PV-2) and
vesicular stomatitis virus (VSV) of organic (OE) and aque-
ous extracts (AE) from: Baccharis gaudichaudiana, Bac
charis spicata, Bidens subalternans, Pluchea sagittalis,
Tagetes minuta and Tessaria absinthioides, all medicinal
plants belonging to the Asteraceae family (Table 1) in
which different compounds from diverse chemical groups
have been found.
The selection of the viruses was based on the clinical
importance of their infections, the type of the genome
and the strategies of viral replication. HSV-1, a DNA
virus, is responsible of viral infections that have in-
creased over the past decades [14] and the development
of therapeutic agents has become necessary due to itsTable 1 Ethnopharmacological and chemical data of the med
Plant species Vernacular
Name
Place of
collection
Popular use
Baccharis
gaudichaudiana
DC
“carqueja”
“chilca
melosa”
Rosario, Santa
Fe, Argentina
Digestive, hepatic, antidiab
urinary and respiratory tra
Baccharis
spicata (Lam.)
Baill.
“carqueja”,
“chilca
blanca”
Rosario, Santa
Fe, Argentina
Medicinal [6]
Bidens
subalternans DC
“amor seco” Ciudad de
Buenos Aires,
Argentina
Ocular antiseptic, to treat
Pluchea
sagittalis (Lam.)
Cabrera
“lucera”
“hierba
lucera”
Zarate, Buenos
Aires,
Argentina
Stomachic, hepatic, choler
cholagogue, antipyretic, a
stomachache, febrifuge, an
Tagetes
minuta L.
“chinchilla” Ibicuy, Entre
Rios, Argentina
Digestive, antispasmodic,
antiseptic, antitussive, pec
infections [10]
Tessaria
absinthioides
(Hook. & Arn.)
“pájaro
bobo”,
“suncho
negro”
Trancos,
Tucuman,
Argentina
Hypocholesterolemic, bals
renal insufficiency [4]growing incidence and the appearance of drug-resistant
strains, especially in immunocompromised patients [15].
Poliovirus is an RNA virus that causes poliomyelitis for
which there are two commercially available vaccines.
Nevertheless, no complete eradication of this viral infec-
tion has been achieved [16]. There is a need to find ef-
fective drugs to complete the eradication plan and to
control future outbreaks [17].
BVDV and VSV cause serious disease in livestock and
are responsible for major losses in cattle. Both are RNA
viruses but BVDV has a positive sense genome while
VSV has a negative one. Moreover, BVDV is also ac-
cepted as a surrogate virus model for identifying and
characterizing antiviral agents to be used against HCV
[18] and VSV has been extensively studied as a prototype
of non-segmented, negative-strand RNA viruses [19].
Besides the results of the antiviral screening, the prelim-
inary characterization of the antiviral effect of the most
active extracts is reported. In addition, the bioassay-
guided fractionation of B. gaudichaudiana organic extract,
altogether with the isolation of its major antiviral com-
pound is also described.
Results
Antiviral activity against BVDV, HSV-1, PV-2 and VSV
Six Argentinean Asteraceaes were selected for this study.
Chemical, ethnopharmacological data and previously
reported antiviral studies are shown in Table 1. The anti-
viral activity of plant extracts against BVDV, HSV-1,
PV-2 and VSV was assessed in vitro by the viral CPE reduc-
tion assay. Results obtained from this screening (Table 2)
showed that B. gaudichaudiana and B. spicata OE were
active against PV-2 and VSV, the AE of both species andicinal plants selected
Chemical composition
etic, antidiarrheal, antiseptic in
ct infections [4]
Flavonoids, clerodane
diterpenoids, phenolics,
hydroxycinnamic acids [5]
Diterpenoids [4]
aphthae and sore throat [7,8] Triterpenoids, steroids [4]
etic, antispasmodic, digestive,
ntitussive, antiseptic, for
tiseptic, for venereal diseases [4,9]
Phenylpropanoids, flavonoids,
essential oils, polyphenols,
tannins, triterpenes [4]
diuretic, antifungal, anthelminthic,
toral, disinfectant, in urinary tract
Terpenoids, flavonoids, essential
oils [11,12]
amic, expectorant, for hepatitis and Sesquiterpenes, sulfur
compounds, flavonoids, essential
oils [13]
Table 2 Screening of antiviral activity of plant extracts
Plant name Extracts Yield
(%)
BVDV HSV-1 PV-2 VSV
Baccharis gaudichaudiana OE 29 - - + +
AE 10 - + - -
Baccharis spicata OE 15.5 - - + +
AE 9 - + - -
Bidens subalternans OE 8.4 - - - -
AE 6.3 - - - -
Pluchea sagittalis OE 11 - +/− - +/−
AE 11 - - - -
Tagetes minuta OE 7.5 - - +/− -
AE 7.8 - - - -
Tessaria absinthioides OE 13.5 - - + -
AE 15.3 - + - -
The antiviral activity was tested by the reduction of viral cytopathic effect
(CPE) assays.
(+) positive: reduction of viral CPE higher than 50% at both
concentrations tested.
(+/−) positive/negative: reduction of viral CPE only achieved at 100 μg/ml.
(−) negative: without protection at 25 and at 100 μg/ml.
OE organic extract, AE, aqueous extract.
Yield (% w/w = g of extracts/100 g of dried and ground plant material).
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and T. absinthioides OE was active only against PV-2.
None of the twelve extracts was active against BVDV.
To confirm the inhibitory effect detected in the screen-
ing, we evaluated the antiviral activity of the positive ex-
tracts by the plaque reduction assay and the SIs were
determined (Table 3). Regarding the active extracts, the
thin layer chromatographic (TLC) profiles of the OE of
the two Baccharis species were very similar. Bands corre-
sponding to flavonoid aglycones and terpenoids were ob-
served after spraying with NPR and anisaldehyde/H2SO4.Table 3 Antiviral activity of selected active extracts
Plant name Extract Virus CC50
a
Baccharis gaudichaudiana OE PV-2 161.0
VSV
AE HSV-1 > 2
Baccharis spicata OE PV-2 114.3
VSV
AE HSV-1 > 2
Tessaria absinthioides OE PV-2 390.1
AE HSV-1 > 2
Acyclovir* HSV-1 >
Guanidine* PV-2 > 8
Ribavirin* VSV >
aCC50 cytotoxic concentration 50,
bEC90 effective concentration 90,
cEC50 effective co
aqueous extract. Results are shown as means ± SD, each time in triplicate.
*Acyclovir, Guanidine and Ribavirin were included as positive controls for the antivi
were expressed in mM (#), except for EC50 of acyclovir that is expressed in μM (
§).On the other hand, Tessaria absinthioides OE showed
strong bands corresponding to flavonoid glycosides and
only weak bands corresponding to terpenoids in the OE
and AE (Additional file 1).
B. gaudichaudiana OE and AE exhibited the highest
SI values against PV-2 (10.9) and HSV-1 (>117), respect-
ively. Based on these results, both extracts were selected
to characterize the antiviral activity.
Characterization of antiviral activity
In order to characterize the antiviral activity against PV-
2 and HSV-1, different experimental approaches were
considered for the OE and AE of B. gaudichaudiana.
In the pretreatment assay, none of the extracts protected
Vero cells against PV-2 or HSV-1 infection after 7 h of in-
cubation at the evaluated concentrations (Figure 1).
When the virucidal activity was assessed, the OE did
not prove to have this effect against PV-2 since 10 and
20% of reduction of viral infectivity was obtained at r.t.
and 37°C, respectively. In contrast, higher values were
obtained for the AE against HSV-1 with values of 85%
and 97%, at r.t. and 37°C, respectively (Figure 1).
With the aim to determine whether the inhibitory ef-
fect of the extracts occurs during the adsorption or post-
adsorption steps of the viral cycle, different experimental
conditions were evaluated with 1xEC90 of OE and AE
(Figure 2A). The results obtained demonstrated that B.
gaudichaudiana OE (30 μg/ml) reduced the formation
of PV-2 plaques when it was added after the adsorption
period. This reduction in the number of plaques was
similar to that obtained when the OE was present during
all the experimental time (Throughout) (Figure 2B).
In contrast, B. gaudichaudiana AE (35 μg/ml) inter-
fered in the adsorption step of HSV-1 to Vero cells and
caused an inhibition degree similar to that obtained(μg/ml) EC90
b (μg/ml) EC50
c (μg/ml) SI d
± 2.5 30.1 ± 0.8 14.8 ± 1.5 10.9
114.0 ± 0.5 33.9 ± 3.8 4.8
000 35.4 ± 1.2 17.1 ± 0.1 > 117
± 4.7 74 ± 4.7 19.3 ± 3.9 5.9
110.1 ± 1.6 23.8 ± 0.1 4.8
000 61.3 ± 3.2 34.7 ± 3.2 > 57.6
± 3.2 61.1 ± 2.8 40.3 ± 5.6 9.7
000 26.5 ± 1.5 19.1 ± 3.2 > 104
9 # 1.9 ± 0.2 § >90000
4 # 0.2 ± 0.6 # > 420
2 # 0.3 ± 1.2 # > 6.7
ncentration 50, dSI (Selectivity index) = CC50/EC50, OE organic extract, AE
ral activity of HSV-1 and PV-2 and VSV, respectively. The CC50 and EC50 values
Figure 1 Virucidal activity and the effect of pretreatment with
B. gaudichaudiana OE and AE. The virucidal activity and the
pretreatment of 10xEC90 (OE= 300 μg/ml AE = 350 μg/ml) and
1xEC90 (OE= 30 μg/ml, AE = 35 μg/ml) were evaluated against PV-2
and HSV-1, respectively. Data represent % of virus inhibition
compared to untreated controls as mean ± SD (n = 3), each time
in quadruplicate.
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The reduction of 25% observed in the post-adsorption
condition could be due to the inhibitory effect of this ex-
tract on the adsorption steps on the subsequent HSV-1
replication cycles occurring during the 48 h incubation
period carried out at 37°C (Figure 2B).
Bioassay-guided fractionation of B. gaudichaudiana OE
B. gaudichaudiana OE was fractionated by a silicagel
column chromatography. Eight final fractions were
obtained according with their TLC profiles. The results
obtained in the evaluation of the anti-PV-2 activity dem-
onstrated that FC was the most active fraction with a
SI = 56.4 and EC50 = 2.1 ± 0.1 μg/ml followed by FD
SI = 44.1 and EC50 = 2.5 ± 0.3 μg/ml (Table 4). The
HPLC profile obtained for FD was similar to that of FC
but based on the SI value and the yield, FC was selected
for further characterization (Additional file 2).
To define the post-adsorption steps of the viral cycle
that could be targeted by FC, the effect of the addition ofFigure 2 Effect of B. gaudichaudiana OE and AE in the adsorption and
Open and black arrows indicate the absence and presence of extract, respe
conditions. 1xEC90 was used for the experiments. Data represented % of vi
each time by quadruplicate.FC (10xEC90 = 22 μg/ml) at different times of infection
on PV-2 production at 10 h p.i. was evaluated (Figure 3).
The results obtained demonstrated that the maximum
inhibition level was exerted when FC was present before
4 h of infection.
A semipreparative HPLC of FC was then performed and
four subfractions (FC1- FC4) were collected. The antiviral
activity against PV-2 was detected in FC2 (EC50 = 3.3 ± 0.3
μg/ml) and FC3 (EC50 = 1.8 ± 0.1 μg/ml) (Figure 4). The
CC50 value of FC3 was higher than 100 μg/ml and the SI
was > 55.6. A major pure compound was isolated from
FC3 by semipreparative HPLC (Figure 5) and identified as
apigenin (Figure 6) by comparison of its spectral data
(Additional file 3 and Additional file 4) with literature
values [20] and by HPLC comparison with a reference
standard (Additional file 5). The antiviral activity of apige-
nin was determined by plaque assay with EC50 = 12.2 ±
3.3 μM. Its CC50 value was 230.7 ± 4.4 μM; in conse-
quence the SI was 18.9. The apigenin standard exhibited
similar values of EC50 and CC50 (data not shown).
Discussion
Several Baccharis species have been reported to have anti-
viral activity: B. genistelloides [21], B. teindalensis [22], B.
trinervis [23], B. coridifolia [24] and B. articulata [25] but
this is the first report on the antiviral activity of B.
gaudichaudiana and B. spicata. Although the virucidal
activity of T. absinthioides essential oil was reported previ-
ously against HSV-1 and Junín virus [13], this is the first
report of the antiviral activity of the OE and AE obtained
from this plant.
In the characterization of the antiviral activity of B.
gaudichaudiana AE, this extract did not affect HSV-1
replication when it was added to the cell culture before
infection, thus, it is unlikely that its antiviral activity
could be due to direct effects on the host’s cell. On thepost-adsorption steps of PV-2. A. Scheme of addition of OE or AE.
ctively. B.- Percentage of viral inhibition under different experimental
rus inhibition compared to untreated control as mean ± SD (n = 3),
Table 4 Antiviral activity of fractions of B. gaudichaudiana
OE
Fraction Yield (%) CC50
a (μg/ml) EC50
b (μg/ml) SIc
FA 1.43 396.7 ± 14.4 15.4 ± 1.0 25.8
FB 1.35 196.1 ± 6.1 7.6 ± 0.4 25.8
FC 2.56 118.5 ± 6.5 2.1 ± 0.1 56.4
FD 0.66 110.2 ± 7.9 2.5 ± 0.3 44.1
FE 2.14 390.9 ± 10.9 38.4 ± 3.8 10.2
FF 1.68 390.4 ± 10.4 33.1 ± 4.8 11.8
FG 0.75 412.3 ± 7.1 27.4 ± 3.9 15.0
FH 0.31 729 ± 3.1 20.8 ± 3.6 35.1
aCC50 cytotoxic concentration 50,
bEC50 effective concentration 50,
cSI
(Selectivity index) = CC50/EC50 Yield (% w/w = g of fraction/100 g of OE).
Results are shown as mean ± SD (n=3), each time in quadruplicate.
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that this extract could interact with viral particles and
inactivate them. Data also indicated that HSV-1 infec-
tion was significant impaired only if the AE was
present at the time of adsorption. Therefore, these
results suggest that AE may exert its antiviral activity
by inactivation of viral particles at high concentra-
tions and possibly by interference of the adsorp-
tion step of the virus to the cells at non-virucidal
concentrations.
Upon characterizing the antiviral activity of B. gaudi
chaudiana OE against PV-2, it could be considered that
this extract had a true antiviral activity against this virus
because of its ability to inhibit the viral cycle, parti-
cularly during the post-adsorption period. In the present
study, B. gaudichaudiana OE was selected for furtherFigure 3 Effect of FC on PV-2 replication cycle. A. Kinetics of PV-2 extra
were infected with PV-2 ( m.o.i. = 10). Viral titers were determined at differe
production during a one step replication cycle At different h p.i. after the a
production was determined at 10 h p.i. of incubation at 37°C, by the plaqu
control. The viral production at 10 h p.i. in the kinetic curve of control virus
with Bonferroni a posteriori test).purification and isolation of antiviral principles by
bioassay-guided fractionation. The most active fraction
obtained, FC, exerted the maximum inhibition of PV-2
replication when it was present before 4 h p.i. At this
time of the poliovirus replication cycle, the synthesis of
viral RNA is maximum [26,27]. Taking into account the
results obtained, it can be deduced that FC might exert
its antiviral activity at an intermediate stage of virus life
cycle and could interfere with viral RNA synthesis and
polyprotein processing/synthesis.
From this active fraction the flavonoid apigenin (5, 7-
dihydroxy-2-(4-hydroxylphenyl)-4H –chromen-4-one) was
isolated. This compound has previously been reported
from B. gaudichaudiana [28]. It has been demonstrated
that apigenin is active against different viruses, including
avian influenza H5N1 virus strain, hepatitis C virus, HSV
and human immunodeficiency virus [29-32].
Although apigenin exhibited antiviral activity against
PV-2 (EC50 = 12.2 ± 3.3 μM), HPLC profile of FC3
showed the presence of other minor compounds which
could be responsible, altogether with apigenin, of the
antiviral activity observed.
Further studies are under way to characterize the
mechanism of action of apigenin against PV-2.
To our knowledge, this is the first time that the anti-
viral activity of B. gaudichaudiana is reported and the
anti-poliovirus activity of apigenin is determined.
Conclusion
In this study we have shown that the organic extract of
B. gaudichaudiana shows high antiviral effect against
PV-2 and the isolated compound, apigenin could be, at
least in part, responsible for the antiviral activitycellular production during one replication cycle Vero cell monolayers
nt hours by plaque assay. B. Effect of addition of FC on the PV-2
dsorption period, FC (22 μg/ml) was added and the extracellular viral
e assay. Data represent % of virus production respect to untreated
was considered 100%. * p < 0.05 vs 0 and vs 2 h (one-way ANOVA
Figure 4 Antipoliovirus (PV-2) activity of subfractions derived
from FC. The antiviral activity of each subfraction was determined
by the reduction of plaque assay. Results are shown as mean ± SD
(n = 3), each concentration in quadruplicate.
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derstanding of the mechanism of action of apigenin.
Moreover, since the aqueous extract of B. gaudichau
diana was active against HSV-1, the bioassay guided frac-
tionation of this extract will be carried out.
Methods
Plant material
Plant samples (aerial parts with flowers) were collected
between 2008 and 2010 in their places of origin in
Argentina. Voucher specimens are deposited as follows:
B. gaudichaudiana (1655): Botany Herbarium at Facultad
de Ciencias Bioquímicas y Farmacéuticas, Universidad
Nacional de Rosario, Argentina; B. spicata (BAF 711),
Bidens subalternans (BAF 704), Pluchea sagittalis (BAF
709) and Tagetes minuta (BAF 714): Herbarium at MuseoFigure 5 HPLC profile of FC3. HPLC: RP-18 column, using a water (A)-met
isocratic 98% A, 26–30 min: 98→ 50% A, flow rate=1 ml/min, monitored a
peak detected.de Farmacobotánica, Facultad de Farmacia y Bioquímica,
Universidad de Buenos Aires; Tessaria absinthioides
(Slanis-Juarez 1041): Herbarium of Fundación Miguel A.
Lillo, Universidad de Tucumán. Botanical and vernacular
names, popular uses and reported chemical composition
are shown in Table 1.Extraction of plant material
Dried aerial parts of each plant (10 g) were reduced to pow-
der and extracted by soaking in 100 ml of dichloromethane:
methanol (1:1) at room temperature (r.t.) for 24 h and then
vacuum-filtered. The process was repeated twice and the
filtrates were combined and dried under vacuum to obtain
the organic extract (OE). The marc of the plant material
was further extracted with distilled water under the same
conditions. The aqueous extracts (AE) were lyophilized. For
the antiviral assays, OE and AE were dissolved in dimethyl-
sulfoxide and sterile distilled water, respectively.Cells and virus strains
Vero cells (ATCC CCL 81) were obtained from Asociación
Banco Argentino de Células and cultured in growth
medium consisting of Eagle’s Minimal Essential Medium
(E-MEM) supplemented with 10% fetal bovine serum
(FBS) (PAA), 100 μg/ml streptomycin, 100 IU/ml penicil-
lin, 2 mM L-glutamine, 2.25 g/L sodium bicarbonate and
non-essential amino acids (100 μM) (Gibco), at 37°C in a
5% CO2 incubator. The infection medium (IM), used for
the antiviral assays, was the same as the growth medium
but 2% FBS was added instead. The plaque medium (PM)
was IM supplemented with 1% methylcellulose (Sigma).
Madin-Darby Bovine Kidney cells (MDBK) (ATCC CLL
22) were grown in growth medium supplemented withhanol (B) gradient: 0–2 50% A; 2–15 min: 50→ 98% A, 15–25 min:
t 336 nm. The insert shows the UV adsorption spectra of the major
Figure 6 Chemical structure of apigenin: 5, 7-dihydroxy-2-
(4-hydroxylphenyl)-4H –chromen-4-one, C15H10O5, MW: 270.24.
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supplemented with 2.5% horse serum (Gibco).
The herpes simplex type 1 (HSV-1) F strain, the polio-
virus type 2 (PV-2) Sabin strain and the bovine viral
diarrhea virus (BVDV:NADL strain cytopathic biotype
were kindly provided by Dr. Albert Epstein, Dr. María
Cecilia Freire (ANLIS-Instituto Dr. Carlos G. Malbrán,
Argentina) and Dr. Laura Weber (INTA, Castelar,
Argentina), respectively. VSV, Indiana strain (ATCC VR-
1421), was purchased from ATCC. Virus stocks of HSV-
1, PV-2 and VSV were propagated and quantified in
Vero cells. BVDV was propagated and quantified in
MDBK cells. Virus quantification was performed by
plaque assay method as number of plaque forming units
per ml (p.f.u./ml). All virus stocks were stored at −70°C
until used.
Screening of antiviral activity
The antiviral activity of each plant extract was screened in
96-well culture plates by measuring the reduction of the
viral cytopathic effect (CPE). Confluent Vero and subcon-
fluent MDBK cell monolayers were infected with HSV-1,
PV-2 or VSV or with BVDV, respectively, at a multiplicity
of infection (m.o.i.) of 0.01 p.f.u./cell in the presence of 25
and 100 μg/ml of each OE/AE. Infected cells in the ab-
sence of extract as control virus and mock-infected cells
with and without extract as control cells and cytotoxicity
control were included. Plates were incubated at 37°C in a
humidified atmosphere containing 5% CO2 until 90% of
viral CPE in the CV was reached. The reduction of viral
CPE was determined by measuring cell viability by the
tetrazolium salt/phenazine methosulfate (MTS/PMS) col-
orimetric assay (CellTiter 96™ Promega, Madison, WI,
USA). The absorbance at 490 nm was measured in a
Multi-Mode microplate reader (Synergy™ HT, BioTek). Re-
sults of the screening were expressed as positive (+) (re-
duction in the CPE at both concentrations tested),
negative (−) (absence of reduction in the CPE) and (+/−)
(reduction in CPE only at 100 μg/ml).Cytotoxicity assay: determination of cytotoxic
concentration 50 (CC50)
The cytotoxic effect of B. gaudichaudiana, B. spicata
and T. absinthioides OE and AE on Vero cells was de-
termined by the MTS/PMS method, as previously de-
scribed [33]. Briefly, subconfluent monolayers of Vero
cells (8×103 cells/well; 24 h culture) were incubated in
quadruplicate in 96-multiwell plates in the presence of
two-fold dilutions of the extracts for 72 h at 37°C. Cell
viability (%) was calculated for each concentration as
Abs treated/Abs CC × 100, where Abstreated and Abs CC
are the absorbance readings for the wells with and
without extract, respectively. The CC50 is defined as
the concentration that reduced cell viability by 50%
with respect to controls without drug. The CC50 value
was derived from the corresponding dose–response
curves. The maximum non-cytotoxic concentration
(MNCC) is defined as the maximum concentration of
the extract that leaves 100% of viable cells.
Antiviral assay: determination of effective concentration
50 (EC50)
The effective concentration 50 (EC50) is the concentration
of extract that reduces the number of viral plaques by 50%
with respect to control virus (without extract). This par-
ameter was determined by the plaque reduction assay.
Briefly, monolayers of Vero cells grown in a 24-well plate
(24 h; 5% CO2; 37°C) were infected with 100 p.f.u./well of
PV-2, VSV or HSV-1 in either the absence or presence of
serial two-fold dilutions from the MNCC of B. gaudi-
chaudiana, B. spicata and T. absinthioides extracts
(treated). After 45 min incubation at 37°C, the viral inocu-
lum was removed, and the cell monolayers were washed
with phosphate buffer saline (PBS) and overlaid with PM
supplemented with the corresponding concentrations of
each extract. PM without extract was added in CC and
CV wells. After 24 h at 37°C for PV-2 and VSV or 48 h for
HSV-1, cell monolayers were fixed and stained with 0.75%
crystal violet in methanol:water (40:60) and viral plaques
were counted. Reduction of plaques (%) was calculated as:
[1-(nº plaques treated/ nº plaques CV)] × 100. The EC50
values were calculated by regression analysis of the dose–
response curves generated with the data.
The selectivity index (SI) was calculated as the CC50/
EC50 ratio.
Acyclovir (Filaxis); Guanidine.HCl (Sigma-Aldrich, St.
Louis, MO) and Ribavirin (MP Biomedicals, LLC) were
tested simultaneously as positive controls for HSV-1,
PV-2 and VSV, respectively.
Chromatographic profile- thin layer chromatography
Chromatographic analysis of positive OE were performed
by thin layer chromatography (TLC) on silica gel layers
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ate:toluene:formic acid:methanol (2:2:1:1) and Natural
Product Reagent (NPR- 2-aminoethildiphenilboric acid -
Sigma) as visualization reagents; and b- toluene:ethylacetate
(5:5) and sulphuric/anisaldehyde (SAni) as reagent. The
positive AE were tested on: a) silica gel layers using
ethylacetate:methanol:water (50:6:5) and SAni reagent; and
b) Cellulose plate (Polygram® CEL 300 UV254 – Macherey
Nagel) using acetic acid 15% and NPR as reagent. In all
cases, the TLC plates were visualized under UV light (254
and 366 nm) and visible light.
Characterization of the antiviral activity
Virucidal activity
The virucidal activity was measured by in vitro incuba-
tion of viruses with the extracts. Briefly, 106 p.f.u. of PV-
2 or HSV-1 were incubated for 30 min at r.t. or at 37°C
with 10xEC90 of B. gaudichaudiana OE (300 μg/ml) or
AE (350 μg/ml), respectively. Simultaneously, the same
amount of virus was incubated with IM without extract
as control. The residual infectious viruses were quanti-
fied by viral plaque assays.
Pretreatment assays
To assess the effect of the pretreatment with B.
gaudichaudiana extracts, Vero cell monolayers seeded
in 24-well plates were treated for 7 h at 37°C with two
concentrations of the extract 10xEC90 and 1xEC90 (OE:
300 and 30 μg/ml and AE: 350 and 35 μg/ml, respect-
ively). Then, the medium was removed and washed with
PBS, and the cell monolayers were infected with 100 p.f.
u. of PV-2 or HSV-1/well in the absence of the extracts.
Mock-infected cells (CC) and cells pretreated with IM
(CV) were included in each assay. After 45 min at 37°C,
the viral inoculum was removed and PM without extract
was added and further incubated at 37°C for 24 or 48 h.
Finally, the number of viral plaques was determined.
Time-of-addition assay
To study the effect of the extracts in the adsorption and
post-adsorption events, three different treatments with
B. gaudichaudiana OE (1xEC90 = 30 μg/ml) against PV-
2 or AE (1xEC90 = 35 μg/ml) against HSV-1 were carried
out. B. gaudichaudiana OE and AE were present: (i)
only during the adsorption period (Adsorption); (ii) after
adsorption and until the end of the experiment (Post-
Adsorption), and (iii) during and after the adsorption
(Throughout). Briefly, Vero cell monolayers cultured in
24-well plates were precooled for 1 h at 4°C. Cells were
then infected with 100 p.f.u. of virus/well in the presence
or absence of OE/AE and further incubated at 4°C for 1
h allowing only the adsorption step of the viral particles
to the cells (Adsorption). Cell monolayers were washed
with PBS, and then PM with or without extract wasadded. The number of viral plaques was determined
after 24 h and 48 h for PV-2 and HSV-1, respectively.
Bioassay-guided fractionation of Baccharis
gaudichaudiana OE
B. gaudichaudiana aerial parts (500 g) were air-dried,
ground to powder and extracted with dichloromethane:
methanol (1:1) and the extract was taken to dryness. Thirty
grams of this OE was fractionated by silica gel 60 (500 g)
column chromatography eluted with a step gradient of
hexane:ethylacetate (100:0 to 0:100) and ethylacetate:
methanol (100:0 to 0:100) to afford 21 fractions of 500 ml
each. Eluates were monitored by thin-layer chromatog-
raphy (TLC) on silica gel 60 F254 using toluene-ethyl acet-
ate (1:1) and cellulose layers using acetic acid 40% and
combined into eight final fractions (FA to FH) according to
their TLC profiles.
Fraction FC was further fractionated by a semipreparative
reverse-phase HPLC (Waters 2996 – Photodiode Array De-
tector–Waters 600 pump) on a RP-18 column (LiChrospher®
100, 5 μm, LiChroCART 125×4 – Merck). The injection vol-
ume was 50 μl. Elution was performed at a flow rate of 1 ml/
min. The mobile phase used consisted of water (A) and
methanol (B): 0–15 min: isocratic 50% A, 15–25 min: 50 →
98% A, 25–30 min: isocratic 98% A, 30–31 min: 98 → 50%
A. Eluates were monitored at 254 nm. Eluates were collected
into four subfractions: FC1 (0–13 min), FC2 (13–20 min), FC3
(20–25 min) and FC4 (25–30 min).
The FC3 subfraction was subjected to reverse-phase
HPLC on RP-18 column (LiChrospher® 100, 5 μm,
LiChroCART 125×4 – Merck), using a water (A)-methanol
(B) gradient: 0–2 50% A; 2–15 min: 50 → 98% A, 15–25
min: isocratic 98% A, 26–30 min: 98 → 50% A and a flow
rate=1 ml/min and a pure compound was isolated. Eluates
were monitored at 336 nm.
The anti-PV-2 activity of fractions FA-FH and sub-
fractions FC1-FC4 and the pure compound was determined
by viral plaque reduction assay at concentrations ranging
from 100 to 0.1 μg/ml in Vero cells. The cytotoxicity and
SI were also evaluated as previously described.
Identification of apigenin
The pure compound obtained from FC3 was identified by
ultraviolet spectroscopy (UV) (Jasco V-630), infrared spec-
troscopy (IR) (Nicolet 380 FT-IR-Smart Multi Bruce
HATR, Zn Se 45°) and HPLC/DAD by comparison with
authentic sample (Sigma-Aldrich, St. Louis, MO) and
comparison with literature data.
One-step replication curve: effect of fraction FC on PV-2
replication
Confluent Vero cell monolayers cultured in a 96-well plate
were infected with PV-2 (m.o.i. = 10) for 1 h at 4°C. Follow-
ing the adsorption period, cells were washed three times, and
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infection (p.i): 0, 2, 4, 6 and 8 h. Cells were further incubated
up to 10 h. At this time, supernatants were collected and
clarified by centrifugation (3,500 × g at 4°C) and the virus
production was determined by viral plaque assays.Statistical analysis
Data are presented as means ± standard deviation (SD). A
one-way ANOVA with Bonferroni a posteriori test was
used to compare differences between groups. A p < 0.05
was considered significant. The EC50 and CC50 values
were calculated using GraphPad Prism software v. 5.01.Additional files
Additional file 1: TLC profile of OE and AE of B. gaudichaudiana,
B. spicata and T. absinthioides. Right Panels (A and B) showed the OE
profiles in silica gel in (A-) ethylacetate:toluene:formic acid:methanol
(2:2:1:1) revealed with NPR at 366 nm; and (B-) toluene:ethylacetate (5:5)
revealed with AniS, at visible light. Left panels (C and D) correspond to
AEs: (C-.) silica gel and ethylacetate:methanol:water (100:10:13) and SAni,
at visible light; and (D-) AE profile in cellulose with AcH 15% and NPR at
366 nm. BG (B. gaudichaudiana); BS (B. spicata) and TA (T. absibthioides).
Additional file 2: HPLC profile of FC and FD from the OE of
B. gaudichaudiana. A gradient of mobile phase system consisting of
water (A) and MeOH (B) used was: 0–15 min: 2→ 98% A; 15–20 min:
isocratic 98% A; 20–21 min: 98 → 2% A.
Additional file 3: UV spectra of purified apigenin. A.- UV spectra with
methanol (MeOH) and MeOH with sodium methoxide (MeONa); B.- UV
spectra with MeOH, MeOH with aluminium chloride (AlCl3), MeOH+AlCl3+
chloridric acid (HCl) and MeOH+AlCl3+HCl 5 minutes later; C.- UV spectra
with MeOH, MeOH+ sodium acetate (AcONa) and MeOH+AcONa+ boric
acid (H3BO4).
Additional file 4: IR spectra of purified apigenin.
Additional file 5: HPLC of standard apigenin (Sigma). The inserts
show the UV adsorption spectra of the major peak detected. HPLC with a
RP-18 column, using a water (A)-methanol (B) gradient: 0–2 50% A; 2–15
min: 50→ 98% A, 15–25 min: isocratic 98% A, 26–30 min: 98 → 50% A,
flow rate=1 ml/min monitored at 336 nm.Competing interests
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